Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 1;30(1):4-13.
doi: 10.1097/MOH.0000000000000741. Epub 2022 Sep 16.

N6-methyladenosine in hematological malignancies: a concise review

Wan-Jie Wang  1 , Ting-Ting Xu, Jing Bao
Affiliations
Review

N6-methyladenosine in hematological malignancies: a concise review

Wan-Jie Wang et al. Curr Opin Hematol. .

Abstract

Purpose of review: Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered.

Recent findings: Over the years, epigenetic abnormalities have been known to act a key part in occurrence and development of hematological tumors. In the internal modifications on long noncoding eukaryotic mRNA, there is a common type called N6-methyladenosine that can change the expression of target genes and participate in the translation, degradation and splicing of mRNA. M6A is related to a wealth of cancers, such as HNRNPA2B1's elevation in multiple myeloma, METTLE3's elevation in acute myeloid leukemia and lung cancer. Immune cells, playing a significant role in hematological cancers, can also be regulated by m6A.

Summary: In the review, we summarized the recent progress on hematological malignancies associating with m6A and immune cells, which may offer a new road for the treatment of them.

PubMed Disclaimer

References

    1. Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell 2017; 31:127–141.
    1. Zucheng X, Meiwei L, Haoyuan H, et al. Expression of N6-methyladenosine (m6A) regulators correlates with immune microenvironment infiltration and predicts prognosis in diffuse large cell lymphoma (DLBCL). Bioengineered 2021; 12:6115–6133.
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046–1060.
    1. Castaneda O, Baz R. Multiple myeloma genomics – a concise review. Acta Medica Academica 2019; 48:57–67.
    1. Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014; 4:e207.

Publication types